diaDexus, Inc. Expands Loan Facility with Comerica to $10 Million

  diaDexus, Inc. Expands Loan Facility with Comerica to $10 Million

Business Wire

SOUTH SAN FRANCISCO, Calif. -- October 22, 2013

diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing
proprietary cardiovascular diagnostic products, today announced that it has
amended its agreement with Comerica Bank to expand its existing loan facility
from $5 million to $10 million. The loan will start to amortize on January 1,
2014 over 36 months on a 42-month basis, with monthly interest payments at a
fixed 6.45 percent interest rate, equal principal payments and an increased
balloon payment of principal on the maturity date. In conjunction with this
loan expansion, diaDexus issued a warrant to Comerica to purchase 96,685
shares of its common stock.

”Our base business is strong, with most cardiovascular specialty labs in the
U.S. offering the PLAC® Test, and we’re now planning for long-term growth
focused on pipeline development and product expansion,” said Brian Ward,
Ph.D., diaDexus’ president and chief executive officer. “This loan facility
will support the identification, licensing and development of product pipeline
opportunities and help us to prepare for the potential submission for
clearance by the Food and Drug Administration of the PLAC Test for Lp-PLA[2
]Activity in 2014.”

"diaDexus has continued to make great strides with 12 consecutive quarters of
year-over-year revenue growth driven by expanding the adoption of the PLAC
Test, which has the potential to help physicians reduce the risk of
cardiovascular disease for their patients,” said Jeff Chapman, senior vice
president and head of Life Sciences at Comerica. “This loan will contribute to
the growth of diaDexus’ sales and product pipeline."

About Comerica Bank's Technology and Life Sciences Division

Comerica Bank's Technology and Life Sciences Division is one of the nation's
leading technology banking practices, offering a wide range of financial
services tailored to corporate customers, entrepreneurs and professionals.
Veteran bankers provide credit and financial services and products to young,
growing, professionally backed technology and life sciences companies, as well
as their more mature counterparts. The Technology and Life Sciences Division
serves all major U.S. technology centers from offices coast-to-coast and its
headquarters in Palo Alto, California. Comerica Bank is a subsidiary of
Comerica Incorporated (NYSE:CMA), a financial services company that is among
the 25 largest U.S. banking companies. For more information, visit
www.comerica.com.

About diaDexus, Inc.

diaDexus, Inc., based in South San Francisco, California, develops and
commercializes proprietary cardiovascular diagnostic products addressing unmet
needs in cardiovascular disease. The company's PLAC® Test ELISA Kit is the
only blood test cleared by the FDA to aid in predicting risk for both coronary
heart disease and ischemic stroke associated with atherosclerosis, the #1 and
#3 causes of death, respectively, in the United States. The company's PLAC®
Test for Lp-PLA[2] Activity, a CE-marked test, is an indicator of
atherosclerotic cardiovascular disease, the #1 cause of death in Europe.
diaDexus is ISO 13485 certified and is manufacturing the PLAC Test for
Lp-PLA[2] Activity on-site. For more information, please visit the company's
website at www.diaDexus.com.

Forward-Looking Statements

This release contains forward-looking statements based on current expectations
and assumptions and entail various risks and uncertainties that could cause
actual results to differ materially from those expressed in such
forward-looking statements. Important factors known to diaDexus that could
cause actual results to differ materially from those expressed in such
forward-looking statements include the timing of the submission for clearance
of the PLAC® Test for Lp-PLA[2 ]Activity Test to the Food and Drug
Administration, the potential for continued growth in revenues and the
potential for expanding the diaDexus pipeline and products. Additional factors
that could cause diaDexus' results to differ materially from those described
in the forward-looking statements can be found in diaDexus' most recent
quarterly report on Form 10-Q and other reports filed with the Securities and
Exchange Commission, and available at the SEC's web site at www.sec.gov. The
information set forth herein speaks only as of the date hereof, and except as
required by law, diaDexus disclaims any intention and does not assume any
obligation to update or revise any forward looking statement, whether as a
result of new information, future events or otherwise.

Contact:

diaDexus, Inc.
Brian E. Ward, Ph.D., 650-246-6400
CEO
or
Jean-Frédéric Viret, Ph.D., 650-246-6400
CFO
investors.diadexus.com
or
Media and Investors:
BrewLife
Joey Fleury, 415-946-1090
jfleury@brewlife.com
 
Press spacebar to pause and continue. Press esc to stop.